WO2006013963A1 - 爪用外用剤 - Google Patents
爪用外用剤 Download PDFInfo
- Publication number
- WO2006013963A1 WO2006013963A1 PCT/JP2005/014406 JP2005014406W WO2006013963A1 WO 2006013963 A1 WO2006013963 A1 WO 2006013963A1 JP 2005014406 W JP2005014406 W JP 2005014406W WO 2006013963 A1 WO2006013963 A1 WO 2006013963A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nail
- mass
- external preparation
- preparation
- alcohol
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
Definitions
- the present invention relates to an external preparation for nail, particularly an external preparation for onychomycosis, and more particularly to an external preparation for nail having good quick-drying, penetrability and durability.
- Ringworm such as tinea pedis (aquatic worms) and ringworm, is a very difficult disease because the pathogen is parasitic in the deep part of the stratum corneum and the drug is difficult to penetrate even if it is treated with an external preparation.
- a film forming agent as an external preparation.
- a liquid drug containing 1-hydroxy-1,2-pyridone an antifungal agent
- a film forming agent based on -trocellulose Patent Document 1
- an antifungal active substance an acrylate ester
- a force such as a marquetry solution containing a copolymer of a methacrylic acid ester (Patent Document 2), etc.
- the penetration of the nail into the stratum corneum was insufficient, and the above problem could not be solved.
- Patent Document 3 describes a preparation further comprising a methacrylic acid 'methacrylic acid methyl copolymer as an optional component in an antifungal pharmaceutical composition comprising terbinafine and ethyl cellulose as essential components.
- Patent Document 4 discloses a film-forming antifungal composition comprising a methacrylic acid / methyl methacrylate copolymer and a lower alcohol.
- all of the compositions described in the above-mentioned publicly known documents do not contain an alcohol-soluble water-soluble polymer and contain water. Due to poor coating properties, do not reapply in a short period (1 to 2 days) There was a problem with ⁇ and ⁇ ⁇ .
- Patent Document 5 discloses an external composition for onychomycosis comprising a combination of hydroxypropylcellulose, a lower alcohol, and acetone or ethyl acetate as a solubilizing agent !, which uses acetone or ethyl acetate. For this reason, the nail is dehydrated and cured after drug application, and the drug absorbability is reduced at the next application.
- Patent Document 6 discloses an antifungal liquid agent for nails using hydroxypropyl cellulose, which is a water-soluble polymer, as a gel-forming agent, but only a water-soluble polymer is used as a film-forming component. As a result, the coating film of the same formulation was peeled off due to bathing, sweating and friction with clothing, and had to be applied daily or several times a day.
- Patent Document 1 Japanese Patent Application Laid-Open No. 62-155205
- Patent Document 2 JP-A-2-264708
- Patent Document 3 Japanese Patent Laid-Open No. 2002-53462
- Patent Document 4 Japanese Patent Laid-Open No. 10-226639
- Patent Document 5 International Publication No. 96Z11710 Pamphlet
- Patent Document 6 Japanese Patent No. 3064423
- An object of the present invention is to provide a pharmaceutical composition suitable for the treatment of diseases of the nail and tissues surrounding the nail, particularly onychomycosis, without the above-mentioned problems.
- a nail external preparation having the following composition exhibits good quick-drying properties, good film durability over a long period of time, It has been found that if it has an effective component releasing ability, it is excellent in coating properties as well as curling, and the present invention has been completed.
- the present invention relates to a hydrophobic film-forming agent, an alcohol-soluble water-soluble polymer, and The present invention relates to an external preparation for nail containing an antifungal agent.
- the present invention also relates to the above-mentioned external preparation for nails, which contains substantially no water in the preparation.
- the present invention also relates to the above external preparation for nail, wherein the hydrophobic film forming agent is selected from the group consisting of methacrylic acid'methyl methacrylate copolymer, alkyl methacrylate / aminoethyl copolymer and ethyl cellulose.
- the present invention relates to the above external preparation for nails, wherein the alcohol-soluble water-soluble polymer is selected from the group consisting of hydroxypropyl cellulose, polybutylpyrrolidone, and hydroxyethyl cellulose.
- the present invention also relates to the above-mentioned external preparation for nails, which further contains a lower alcohol as a solvent.
- the present invention further provides the nail wherein the amount of the hydrophobic film forming agent is 10 to 30% by mass in the preparation, and the amount of the alcohol-soluble water-soluble polymer is 0.1 to 1.0% by mass in the preparation. It relates to topical preparations.
- the hydrophobic film-forming agent forms a film that is difficult to be removed in daily life, thereby enabling continuous release of the active ingredient, while being soluble in alcohol.
- the water-soluble polymer promotes the natural peeling of the film by bathing, etc., and gives the formulation an appropriate viscosity, improving the adhesion and applicability to the curved upper nail.
- no water is required, it is excellent in quick-drying and can achieve good film properties.
- no solubilizing agents such as cetyl acetate acetate are required, it is possible to prevent a decrease in the permeability of the active ingredient due to dehydration and hardening of the nail and to improve the release of the active ingredient from the preparation. To do.
- the nail external preparation of the present invention has not only excellent quick-drying properties, adhesion properties, and applicability, but also good coating properties for an appropriate period in the treatment plan. Can be held. For example, while the active ingredient is released in an effective amount, the coating with the external preparation continues to adhere to the nail, but after that period, a special removal operation, for example, a removal operation with a removal solution, etc. is required. Natural peeling. In addition, for the external preparation of the present invention, it is possible to arbitrarily adjust the period until natural peeling mainly by increasing or decreasing the blending ratio of the alcohol-soluble water-soluble polymer.
- the present invention In this external preparation for nail, the active ingredient can be allowed to penetrate into the affected area for a long period of one week or longer, so that the application interval can be set within a range that the user can easily tolerate. Therefore, the external preparation for nail of the present invention has an exceptional usability that is unrivaled by its strength, which has excellent therapeutic effects, and significantly improves the user's compliance and improves the therapeutic efficiency. Improvement can be expected.
- the external preparation of the present invention can contain various active ingredients, it can be used for the treatment of various diseases related to the nail and surrounding tissues such as peritonitis, psoriasis, and melanoma, as well as onychomycosis. Can be used.
- FIG. 1 is a graph showing the time course of human nail permeability of an active ingredient in a preparation.
- the external preparation of the present invention contains a hydrophobic film-forming agent, an alcohol-soluble water-soluble polymer, and an active ingredient for treating the target disease as essential ingredients.
- methacrylic acid'methyl methacrylate copolymer alkyl methacrylate'aminoethyl copolymer, ethyl cellulose and the like can be used.
- the blending amount of the hydrophobic film-forming agent is preferably 10 to 20% by mass, particularly preferably 12 to 18% by mass in the preparation. That is, if it is 10% by mass or more, it is possible to obtain a uniform film with little unevenness in the film, and if it is 20% by mass or less, sufficient solubility can be obtained and a uniform solution can be obtained.
- hydroxypropylcellulose which can use hydroxypropylcellulose, polyvinylpyrrolidone, hydroxyethylcellulose and the like, is particularly preferred.
- the alcohol-soluble water-soluble polymer is preferably blended in an amount of 0.1 to 1.0% by mass, particularly 0.2 to 0.7% by mass. That is, when the content is 0.1% by mass or more, it is possible to prevent the occurrence of dripping due to insufficient viscosity, and it is possible to spontaneously remove the coating that does not require removal with a solvent. Eliminating stringing due to excessive size And sufficient quick-drying can be obtained. In addition, if a small amount of the alcohol-soluble water-soluble polymer is blended, the period until the film is naturally peeled can be kept long, and conversely if it is blended in a large amount, the film can be naturally peeled early.
- the active ingredient of the external preparation of the present invention includes drugs effective for the treatment of diseases of the nail and surrounding tissues of the nail, such as onychomycosis, peritonitis, psoriasis, melanoma, such as antifungal agents, antifungal agents, Examples include fungicides, antiviral agents, anti-inflammatory agents, immunomodulators, antitumor agents, and vitamins, with antifungal agents being particularly preferred.
- the antifungal agent is not particularly limited as long as it is a substance having an antifungal action.
- a benzylamine antifungal agent such as butenafine hydrochloride, an arylamine antifungal agent such as terbinafine hydrochloride, neticonazole hydrochloride, ketoconazole.
- An imidazole antifungal agent such as can be used.
- a drug having a high permeability to the nail is preferable.
- the compounding amount of the active ingredient is preferably 0.5 to 10% by mass, particularly preferably 1 to 8% by mass in the preparation.
- the external preparation of the present invention may contain a lower alcohol as a solvent in addition to the above components.
- the lower alcohol is not particularly limited, but ethyl alcohol, isopropyl alcohol, etc. can be used, and ethyl alcohol is preferably used among them.
- the blending amount of the lower alcohol is preferably 60 to 85% by mass, particularly preferably 70 to 80% by mass in the preparation.
- the external preparation of the present invention includes, in addition to the above, oily base materials (fatty acid esters such as diisopropyl adipate, decyl sebacate, isopropyl myristate, isopropyl palmitate, higher alcohols such as oleyl alcohol, 1 menthol, etc. , Crotamiton, etc.), surfactants, wetting agents (polyhydric alcohols such as 1,3 butylene glycol, trehalose, urea, lactic acid, etc.), antioxidants, preservatives, chelating agents, fragrances, etc. .
- the external preparation of the present invention can be obtained by mixing the above components by a usual method.
- the external preparation of the present invention preferably contains substantially no water. That is, the external preparation of the present invention does not contain water other than water that is accidentally mixed during the production process or storage, and the water content of the external preparation of the present invention is preferably less than 5% by mass, particularly preferably. 2 Less than mass%. Moreover, the external preparation of the present invention preferably contains substantially no volatile ketone compound and ester compound. That is, the preferred external preparation of the present invention does not contain the above-mentioned compounds other than those accidentally mixed during the production process or storage.
- the volatile ketone compound and ester compound refer to acetone, ethyl acetate, methyl ethyl ketone, methyl isobutyl ketone, propyl acetate, and butyl acetate, and the above compounds in the external preparation of the present invention.
- the content is preferably less than 5% by weight, particularly preferably less than 2% by weight.
- the external preparation is substantially free of water and volatile ketone compounds and ester compounds.
- Butenafine hydrochloride 5 mass 0/0, sebacic acid Jechiru 2 wt% Oyobi ethanol 79.5 mass 0/0 were mixed and dissolved, while stirring hydroxypropylcellulose 0.5 mass 0/0 and methacrylic acid methacrylic
- the acid methyl copolymer was added in an amount of 13% by mass to obtain a uniform preparation.
- the amount% ethanol 45. 5 wt% Oyobi acetone 30 wt% were mixed and dissolved, stirring hydroxypropylcellulose 0.5 mass 0/0 and methacrylic acid 'methyl methacrylate copolymer 15% by mass was added while, uniform Preparation was obtained.
- Butenafine hydrochloride 5% by mass, 1,3-butylene glycol 2% by mass, ethyl sebacate 2% by mass, ethanol 79% by mass and ethyl acetate 10% by mass are mixed and dissolved, and hydroxypropyl cellulose 2% 0 with stirring. / 0 was added to obtain a uniform formulation.
- Table 1 shows the compositions of the preparations of Examples 1 to 3 and Comparative Examples 1 to 7.
- Mouth-base 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 2 _ 2 0.5 methacrylic acid
- the end point was the point where no change occurred.
- the preparation was applied to the left hand nail using a marquetry applicator with a brush at the tip, and its applicability was evaluated.
- the results were as follows.
- Example 2 An appropriate amount could be applied uniformly without dripping.
- Comparative Example 5 Since the viscosity was low, the liquid dripped around the nail and a liquid pool was formed at the boundary with the skin part. Comparative Example 6: Although dripping did not occur due to high viscosity, uniform application was not possible on the nail, and stringing was observed.
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006531586A JP5059408B2 (ja) | 2004-08-05 | 2005-08-05 | 爪用外用剤 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004-229663 | 2004-08-05 | ||
JP2004229663 | 2004-08-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006013963A1 true WO2006013963A1 (ja) | 2006-02-09 |
Family
ID=35787241
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/014406 WO2006013963A1 (ja) | 2004-08-05 | 2005-08-05 | 爪用外用剤 |
Country Status (2)
Country | Link |
---|---|
JP (1) | JP5059408B2 (ja) |
WO (1) | WO2006013963A1 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014508146A (ja) * | 2011-02-11 | 2014-04-03 | モーベリ・ファルマ・エイビイ | 抗真菌組成物 |
WO2016159532A3 (ko) * | 2015-03-28 | 2016-11-24 | 한국콜마주식회사 | 시크로피록스 함유 네일락카 조성물 |
JP2022552252A (ja) * | 2019-10-08 | 2022-12-15 | ハルクス,インコーポレイテッド | 爪真菌症治療用組成物及び方法 |
WO2024024520A1 (ja) * | 2022-07-28 | 2024-02-01 | 花王株式会社 | 外用剤組成物 |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS62155205A (ja) * | 1985-12-19 | 1987-07-10 | ヘキスト・アクチエンゲゼルシヤフト | 抗真菌性のマニキユア液 |
JPH01149722A (ja) * | 1987-12-08 | 1989-06-12 | Shionogi & Co Ltd | 被膜形成性抗真菌剤組成物 |
JPH02264708A (ja) * | 1989-02-24 | 1990-10-29 | F Hoffmann La Roche Ag | マニキユア |
WO1994015591A1 (en) * | 1993-01-12 | 1994-07-21 | Hisamitsu Seiyaku Kabushiki Kaisha | Onychomycosis remedy composition |
WO1996011710A1 (fr) * | 1994-10-13 | 1996-04-25 | Hisamitsu Pharmaceutical Co., Inc. | Preparation externe pour onychomycose |
JPH09504510A (ja) * | 1993-07-28 | 1997-05-06 | ファイザー・インコーポレーテッド | 爪用の抗真菌性液剤 |
JPH10226639A (ja) * | 1996-12-10 | 1998-08-25 | Shiseido Co Ltd | 被膜形成性抗真菌剤組成物 |
JP2002053462A (ja) * | 2000-08-10 | 2002-02-19 | Pola Chem Ind Inc | 抗真菌医薬組成物 |
JP2002512187A (ja) * | 1998-04-17 | 2002-04-23 | バーテック ファーマシューティカルズ,インコーポレイティド | 爪真菌病の処置のための局所製剤 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT983037E (pt) * | 1998-02-09 | 2003-09-30 | Macrochem Corp | Verniz para unhas antifungico |
US7074392B1 (en) * | 2000-03-27 | 2006-07-11 | Taro Pharmaceutical Industries Limited | Controllled delivery system of antifungal and keratolytic agents for local treatment of fungal infections |
CA2489854A1 (en) * | 2002-06-18 | 2003-12-24 | Pola Chemical Industries Inc. | Antifungal medicinal compositions |
JP2004083439A (ja) * | 2002-08-23 | 2004-03-18 | Ss Pharmaceut Co Ltd | 爪用抗真菌外用剤 |
-
2005
- 2005-08-05 JP JP2006531586A patent/JP5059408B2/ja active Active
- 2005-08-05 WO PCT/JP2005/014406 patent/WO2006013963A1/ja active Application Filing
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS62155205A (ja) * | 1985-12-19 | 1987-07-10 | ヘキスト・アクチエンゲゼルシヤフト | 抗真菌性のマニキユア液 |
JPH01149722A (ja) * | 1987-12-08 | 1989-06-12 | Shionogi & Co Ltd | 被膜形成性抗真菌剤組成物 |
JPH02264708A (ja) * | 1989-02-24 | 1990-10-29 | F Hoffmann La Roche Ag | マニキユア |
WO1994015591A1 (en) * | 1993-01-12 | 1994-07-21 | Hisamitsu Seiyaku Kabushiki Kaisha | Onychomycosis remedy composition |
JPH09504510A (ja) * | 1993-07-28 | 1997-05-06 | ファイザー・インコーポレーテッド | 爪用の抗真菌性液剤 |
WO1996011710A1 (fr) * | 1994-10-13 | 1996-04-25 | Hisamitsu Pharmaceutical Co., Inc. | Preparation externe pour onychomycose |
JPH10226639A (ja) * | 1996-12-10 | 1998-08-25 | Shiseido Co Ltd | 被膜形成性抗真菌剤組成物 |
JP2002512187A (ja) * | 1998-04-17 | 2002-04-23 | バーテック ファーマシューティカルズ,インコーポレイティド | 爪真菌病の処置のための局所製剤 |
JP2002053462A (ja) * | 2000-08-10 | 2002-02-19 | Pola Chem Ind Inc | 抗真菌医薬組成物 |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014508146A (ja) * | 2011-02-11 | 2014-04-03 | モーベリ・ファルマ・エイビイ | 抗真菌組成物 |
WO2016159532A3 (ko) * | 2015-03-28 | 2016-11-24 | 한국콜마주식회사 | 시크로피록스 함유 네일락카 조성물 |
JP2018507225A (ja) * | 2015-03-28 | 2018-03-15 | コルマー コリア カンパニー リミテッドKolmar Korea Co., Ltd. | シクロピロックス含有ネイルラッカー組成物 |
US11154542B2 (en) | 2015-03-28 | 2021-10-26 | Genuone Sciences Inc. | Nail lacquer composition containing ciclopirox |
JP2022552252A (ja) * | 2019-10-08 | 2022-12-15 | ハルクス,インコーポレイテッド | 爪真菌症治療用組成物及び方法 |
WO2024024520A1 (ja) * | 2022-07-28 | 2024-02-01 | 花王株式会社 | 外用剤組成物 |
Also Published As
Publication number | Publication date |
---|---|
JP5059408B2 (ja) | 2012-10-24 |
JPWO2006013963A1 (ja) | 2008-05-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4139860B2 (ja) | 浸透増強および刺激減少システム | |
JP5850889B2 (ja) | 薬物の皮膚送達のための接着性外皮形成製剤とそれを使用する方法 | |
JP5290582B2 (ja) | 爪用医薬組成物 | |
US20200155475A1 (en) | Transdermal Drug Delivery System | |
FR2814074A1 (fr) | Nouvelles compositions estro-progestatives topiques a effet systemique | |
JP4253047B2 (ja) | 被膜形成性抗真菌剤組成物 | |
NZ551887A (en) | Organo-gel formulations for therapeutic applications | |
CN1231592A (zh) | 作为渗透促进剂的羟乙酸及其盐的脂肪酸酯 | |
TW200418487A (en) | Pharmaceutical composition for topical delivery of meloxicam comprising an amine or amine as penetration enhancer. | |
JP2005501883A (ja) | セルタコナゾールを含む爪の機能障害および疾患の治療用の膏薬 | |
TW201018448A (en) | Pressure-sensitive adhesive matrix patch device for the treatment or prevention of onychomycosis or tinea pedis | |
JP4359140B2 (ja) | 異常な角質性物質を除去するための製剤 | |
JP5059408B2 (ja) | 爪用外用剤 | |
WO2003105841A1 (ja) | 抗真菌医薬組成物 | |
RU2564944C1 (ru) | Мазь с метронидазолом, экстрактом личинок большой восковой моли и анестезином для комплексного лечения воспалительных заболеваний пародонта | |
JPH10236918A (ja) | 皮膚貼付剤 | |
EP1732525B1 (fr) | Patch d'amorolfine pour le traitement de l'onychomycose | |
JPH0818983B2 (ja) | 水虫治療剤 | |
JP4803511B2 (ja) | 抗真菌医薬組成物 | |
JPH111433A (ja) | トルナフテ−ト含有液剤 | |
BE1003001A6 (fr) | Composition a mettre en oeuvre pour le traitement de la calvitie, et procedes faisant usage de celle-ci. | |
JPH0755911B2 (ja) | 経皮吸収促進剤及びこれを含有する皮膚外用製剤 | |
JP2001220314A (ja) | 酒粕と日本酒を主原料とする健康・美容剤の製造方法とその製造法により得た健康・美容剤 | |
WO2018116190A1 (en) | Topical sprayable compositions of ketorolac tromethamine | |
JPH06116145A (ja) | 塩酸クロニジンの経皮吸収型製剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006531586 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |